Efficacy of the CV‑MED regimen in treating extramedullary involvement of multiple myeloma: A case report
- Authors:
- Published online on: October 14, 2024 https://doi.org/10.3892/ol.2024.14745
- Article Number: 612
-
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Extramedullary progression of multiple myeloma (MM) is commonly associated with a poor prognosis. However, optimal management strategies have not yet been established for the treatment of extramedullary involvement in MM. The present study reports the case of a 59‑year‑old female patient with MM who experienced extramedullary progression after two cycles of first‑line VRD (bortezomib, lenalidomide and dexamethasone) therapy. The patient achieved remission of the extramedullary lesion following treatment with an innovative CV‑MED regimen, which includes chidamide, bortezomib, mitoxantrone hydrochloride liposome, etoposide and dexamethasone. Subsequently, the patient underwent autologous hematopoietic stem cell harvesting and maintenance therapy, and remains in a progression‑free survival state. The present case suggests that a chemotherapy regimen incorporating mitoxantrone hydrochloride liposomes, chidamide and bortezomib could be a promising treatment strategy for managing extramedullary involvement in MM.
